A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Bevacizumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Cervical cancer; Endometrial cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.
- 04 May 2018 Planned initiation date changed from 1 Apr 2018 to 31 May 2018.
- 28 Mar 2018 New trial record